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PMH13
THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT
OF MAJOR DEPRESSIVE DISORDER IN JAPAN
Nakahara N1, Kamae I2,Yanagisawa S2
1Kobe University,Tokyo, Japan; 2Kobe University, Kobe, Japan
OBJECTIVES: To assess the cost-effectiveness of paroxetine
(PX) compared with conventional tricyclic antidepressants
(TCA’s) for major depressive disorder in Japan. METHODS: A
decision analytic model was built in order to compare three reg-
imens: 1) initiating with PX followed by a TCA (PX-TCA’s); 2)
a TCA followed by PX (TCA’s-PX); and 3) TCA’s only. The deci-
sion tree incorporated the probabilities of dropping out of
therapy obtained from a meta-analysis of randomized controlled
trials in Japan, and also relapse or recurrence probabilities of
depressive symptoms employed from published literature.
Resource use and costs were estimated by the national health
insurance (NHI) scoring system. Health related quality of life
was incorporated in the model using utility values in the litera-
ture. The analysis was performed from a patient perspective
during nine months including the follow-up period. The sensi-
tivity analyses were conducted to test the robustness of the
results. RESULTS: The average costs per patient for each
regimen of the PX-TCA’s, the TCA’s-PX and the only TCA’s were
estimated with 4676€, 4541€ and 5045€, respectively. Regard-
ing the utility analysis, the PX-TCA’s best contributed to gain
with incremental cost-effectiveness ratio of 5587€/QALY. The
average cost per patient for each regimen of the PX-TCA’s or 
the TCA’s-PX remained lower than that of the only TCA’s over
the ranges of the sensitivity analyses. CONCLUSIONS: A treat-
ment for major depression using PX combined with TCA’s was
cost-saving in terms of average costs per patient, comparing to
the treatment by the TCA’s alone. The ﬁrst choice of PX did not
reduce the average cost towards the ﬁrst choice of TCA’s in the
combined treatment. When quality of life of patients incorpo-
rated, the ﬁrst choice of PX was best recommended among the
three strategies.
PMH14
THE HEATLH—RELATED QUALITY OF LIFE OF CHILDREN
SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
Hakkaart L1, Zwirs B2, Buitelaar J3, Schulpen T2,Vlasveld L4,
Bouwmans C1, Rutten F1,Veraart C5
1Institute for Medical Technology Assessment, Rotterdam,
Netherlands; 2University Medical Center Utrecht, Utrecht,
Netherlands; 3University Medical Centre st Radboud Nijmegen;
4Reinier de Graaf Group, Delft; 5Eli Lilly,The Netherlands
OBJECTIVES: The objective of this study is to estimate the
Health Related Quality of Life (HRQoL) of ADHD children and
the societal costs for The Netherlands. METHODS: An initial
population of 10,000 children aged 6–8 years were rated by their
schoolteachers to determine the probability of ADHD. A total
of 150 children with low scores (low probability) and 150 with
high scores were invited for a detailed prospective assessment of
the burden of illness for patient and relatives. We collected data
from the mother on health care utilization and HRQoL of 3 cat-
egories children, e.g. children in the community with high scores
(group 1), clinical ADHD children (group 2) and controls with
low scores (group 3), at 4 moments in time (baseline, t = 6
months, t = 12 months and t = 18 months). The Child Health
Questionnaire (CHQ-PF50) was used for measuring the
HRQoL. Additionally, health care utilization and productivity
loss of the mother of the respondents were assessed by using the
Trimbos and iMTA questionnaire on Costs associated with Psy-
chiatric illness’ (TiC-P). RESULTS: At baseline, we distributed a
total of 165 questionnaires for the 3 groups. The response rates
were; group 1: 94% (n = 33), group 2: 90% (n = 64) and group
3: 78% (n = 47) respectively. Of group 1, 33% of the respon-
dents were identiﬁed as ADHD by a paediatrician. Except for
physical function, group 2 (ADHD patients) scored signiﬁcant
worse on social and emotional functioning and the health care
costs were higher than group 1 and 3. CONCLUSIONS: Chil-
dren suffering from ADHD had worse HRQoL and higher health
care costs than the controls.
PMH15
ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN
CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN
SWEDEN
Myren KJ1, Gillberg C2, Nydén A2
1Eli Lilly Sweden AB, Solna, Sweden; 2Göteborg University,
Gothenburg, Sweden
OBJECTIVES: The objective of the study was to calculate annual
costs in children with AS/HFA, ADHD and RD/WD, and to
explore which variables explained the variations in costs.
METHODS: Sixty boys—20 with high-functioning autism or
Asperger syndrome (AS/HFA), 20 with attention deﬁcit hyper-
activity disorder (ADHD) and 20 with reading and writing dis-
order (RD/WD)—participated in 1994 in an evaluation project
in Göteborg, Sweden. In 2003, a second follow up was under-
taken in 56 boys and their families. Cross sectional data on out-
patient and inpatient care for the child, and indirect resource use
for the families, e.g. time taken off from work and school assis-
tance was collected through questionnaires. Local unit costs and
prices were then applied to calculate annual costs. The parents
also ﬁlled out the Child Health Questionnaire (CHQ-PF50).
RESULTS: A total of 52 families responded to the question-
naires. The mean age was 18 years. The mean annual costs (SEK)
were 67,000, of which indirect costs were 62,500 and direct
costs 4500. Children with AS/HFA and ADHD had mean costs
of 89,800 and 86,500, compared to 23,400 in children with
RD/WD. Multiple regression analysis showed a strong correla-
tion between costs and the psychosocial summary score of the
CHQ: Total annual costs = 330,000 - 5800 ¥ PsS (r = -0.70).
Children with a PsS score below the median (47), had signiﬁ-
cantly higher total costs (SEK104,000 vs. 27,000) and indirect
costs (SEK97,000 vs. 24,000) than children with scores above
the median. CONCLUSIONS: These results emphasize that the
indirect costs in child neuropsychiatric disorders are signiﬁcant,
representing more than 90% of the total costs. The variation in
annual costs is explained, to a great extent, by psychosocial
impairments. The results indicate that a treatment, which
improves the psychosocial functioning of the child and family,
may have signiﬁcant potential in reducing family and societal
costs.
PMH16
TOTAL HEALTH CARE CONSUMPTION AND COSTS OF
SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS
Veraart C1, De Boo A2
1Lilly Nederland BV, Houten, Utrecht, Netherlands; 2Vektis, Zeist,
Utrecht, Netherlands
OBJECTIVES: To estimate health care utilization and costs for
sickness fund insured patients receiving methylphenidate for
ADHD treatment in The Netherlands during 1999–2001.
METHODS: Retrospective analysis was conducted on a medical
and pharmacy claims database of the national sickness funds.
Patients using methylphenidate (MPH, n@13,000) were selected
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by age, i.e., children and adolescents (Group A: 5–19) and adults
(Group B: 20+) and compared against an age matched control
group (Group C) (n = 10,2 million). Hospital admissions, out-
patient clinic visits, total nursing days, average length of stay
(ALOS), total hospital and specialist costs were analysed. Data
for the Control group (C) were based on 2001. Data are pre-
sented as a three-year average or otherwise speciﬁed. RESULTS:
The average number of hospital admissions and total nursing
days were; 434(A), 455(B), and 3159(A), 3691(B) respectively.
ALOS (days) were 7.3(A) and 5.3(C). In total there were
8696(A), 2680(B) outpatient clinic visits. Age matched controls
for category (A) had 88,134 days. Males (MPH group) account
for 78% of the total hospital admissions and 86% of outpatient
clinic visits. Sixty percent of the outpatient visits in MPH cate-
gory (A) occurred in age group 10–14, but 26% in age-matched
controls. Total hospital costs were 2800 M€ (A), 2840 M€ (B)
and 47,640 M€ (C) respectively. Specialist costs involved were
0.743 M€ (A), 0.344 M€ (B) and 7750 M€ for 5–19 years (C).
For the MPH group 21% and 28% of these costs were attrib-
uted to patients aged 5–19 years. Nearly 80% of the specialist
and hospital costs were dedicated to males. Average per patient
hospital costs were 258€(A) and 176€(C). CONCLUSIONS: The
data presented here show that ADHD patients have a substan-
tial health care consumption and related health care costs.
PMH17
COST-UTILITY ANALYSIS OF MEDICAL CO-PRESCRIPTION OF
HEROIN COMPARED WITH METHADONE MAINTENANCE
TREATMENT FOR CHRONIC,TREATMENT RESISTANT
HEROIN ADDICTS
Dijkgraaf MGW1,Van der Zanden BP1, De Borgie CAJM1,
Blanken P2,Van Ree JM2,Van den Brink W1
1Academic Medical Center / University of Amsterdam, Amsterdam,
Netherlands; 2University Medical Centre Utrecht, Utretch, Germany
OBJECTIVES: To determine the cost utility of medical co-pre-
scription of heroin compared with methadone maintenance
treatment for chronic, treatment resistant heroin addicts.
METHODS: In a Dutch multicenter study, 430 patients were
randomly assigned to a 1-year maintenance treatment with
methadone (maximum 150mg per day) or with methadone in
combination with inhalable or injectable heroin (maximum 1000
mg per day). Psychosocial treatment was offered throughout.
The primary outcome measures were the one-year costs from a
societal perspective and the number of quality adjusted life years
(QALYs) based on responses to the EQ-5D at baseline and at
various times during the treatment period. The incremental costs
per QALY ratio was calculated along with its 95% bootstrapped
conﬁdence interval. RESULTS: Co-prescription of heroin gener-
ated 0.058 (95% CI: 0.017–0.100) more QALYs on average than
treatment with methadone alone. Mean cost differences between
coprescribed heroin treatment and standard methadone treat-
ment resulted from the maintenance programme itself (17,634€
vs. 1412€ euro), law enforcement (8756 v 12,885 euro), damage
to victims (9617€ vs. 34,991€), and travel (600€ vs. 146€). The
mean total net costs resulting from co-prescribed heroin treat-
ment amounted to minus 12,793 (95% CI: -1049 to -25,169)€.
The incremental cost per QALY was minus 220,569 (95% CI: -
12,252 to -873,193)€. The cost acceptability of co-prescription
of heroin was more than 98.5% for willingness to pay values up
to 50,000€ per additional QALY. The probability of heroin co-
prescription being cost-effective for patients who were illegally
inactive at baseline was below 42%. The results were robust for
the exclusion of the initial implementation costs of heroin treat-
ment. CONCLUSIONS: Co-prescription of heroin is cost-
effective compared with treatment with methadone alone, even
in disregard of the intangible costs of victims of crime.
PMH18
ASSESSING THE TOTAL COST OF CARE FOR CEREBRAL
PALSY PATIENTS WHO USE BOTULINUM TOXIN TYPE A:
AN APPROACH TO CONTROLLING BIAS IN CASE CONTROL
STUDIES
Dickson M1, Kozma C2, Barron RL3
1University of South Carolina, Columbia, SC, USA; 2Independent
Outcomes Consultant, West Columbia, SC, USA; 3Allergan
Pharmaceuticals, Irvine, CA, USA
OBJECTIVES: The total cost of care (TC) for children with cere-
bral palsy (CP) who use botulinum toxin type A (BTX-A) was
compared to the TC for CP children not using BTX-A.
METHODS: A nested case control design compared BTX-A users
and non-users in the South Carolina Medicaid program from
1995 through 2001. Patients with at least one CP diagnosis
between 1996 and 1999 who were age 18 or younger were
included. They were followed for one year prior to study enroll-
ment, and 24 months after enrollment. A 1 :6 match of BTX-A
users to CP patients (non-BTX-A users) was performed using
propensity scores from a logistic regression model predicting
BTX-A use with demographics, CP severity, analgesia use, inpa-
tient hospitizations, Chronic Disease Score, CP comorbidities,
and pre-period TC. Cases and controls were compared using
logistic regression on post-period data to estimate the same model
predicting BTX-A use. RESULTS: BTX-A users (n = 58) were
identiﬁed and matched to 348 randomly selected non-users. After
matching, the cases and controls were not statistically different
on any of the model variables used in the matching procedure.
Estimation of the ﬁnal model revealed that only CP severity was
signiﬁcantly related to BTX-A use (diplegia p = 0.0107, hemi-
plegia p < 0.0001, and quadraplegia p < 0.001). The Hazard Ratio
for these variables revealed the likelihood of BTX-A use relative
to the lowest CP severity level (diplegia HR = 5.91, hemiplegia
HR = 23.88, and quadraplegia HR = 10.22). While BTX-A is
most frequently used in more severe patients, a statistically sig-
niﬁcant difference in total cost of care was not found (p = 0.528).
CONCLUSIONS: While a greater percentage of CP children
treated with BTX-A had more severe diagnoses, their TC was not
different from CP children not using BTX-A after controlling for
prior-period conditions using propensity scores.
PMH30
COST-EFFECTIVENESS ANALYSIS IN THE AUSTRALIAN
SETTING OF RISPERIDONE LONG-ACTING INJECTION FOR
THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA WHO
ARE PARTIALLY ADHERENT TO THEIR MEDICATION
Crowley S1, Schrover R1, Neville AM2
1Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia; 2Pretium, Sydney,
NSW, Australia
OBJECTIVES: To evaluate the cost-effectiveness of the ﬁrst long-
acting atypical anti-psychotic injection (risperidone long-acting
injection), compared to a weighted comparator of oral risperi-
done, oral olanzapine and typical depot injections for the man-
agement of patients with schizophrenia, who are partially
adherent to their medication in the specialized public psychiatry
setting. The perspective of the analysis was the Australian health
care system. METHODS: A 1-year decision analytic model was
developed using probabilistic sensitivity analysis to explore
uncertainty. The outcomes used in the cost-effectiveness analysis
(CEA) were relapses avoided, deaths due to suicide averted and
